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Abstract
 Background & Aim—Recent basic mechanistic studies found that proton pump inhibitors 
(PPIs) or histamine antagonists inhibited multiple pathways involved in non-alcoholic fatty liver 
disease (NAFLD) development. The aim of this study was to investigate an association between 
PPIs or H1/H2-receptor antagonists (H1RAs/H2RAs) use and NAFLD prevalence in the general 
US population.
 Methods—We conducted a cross-sectional analysis of data from the National Health and 
Nutrition Examination Survey, 2001 – 2006. We included 10,398 adults aged 20 – 74 years who 
had alanine aminotransferase (ALT) data; of those, 2,058 were identified as having NAFLD and 
8,340 as controls. PPIs or H1RAs/H2RAs use was defined as use of prescription medications in 
the preceding month. The length of use was categorized as ≤ 60 days and > 60 days. NAFLD was 
defined as elevated serum aminotransferases without any indication of other causes of chronic 
liver disease.
 Results—In the multivariate unconditional logistic regression analysis, H2RAs use was 
inversely associated with prevalent NAFLD (odds ratio [OR] = 0.43, 95% confidence interval [CI] 
0.18 – 0.99), a finding that was primarily limited to men (OR = 0.18, 95% CI 0.04 – 0.79) and 
those with insulin resistance (OR = 0.22, 95% CI 0.05 – 0.95). However, no significant 
associations were found between PPIs or H1RAs use and prevalent NAFLD.
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 Conclusion—These findings, from the first human study to investigate an association of PPIs 
or H1RAs/H2RAs use with NAFLD, suggest that H2RAs use may be associated with a lower 
prevalence of NAFLD, primarily among men with insulin resistance.
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 INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases 
worldwide. It comprises of the spectrum of fatty liver disease in individuals without 
significant alcohol consumption, ranging from simple steatosis to steatohepatitis (NASH) 
and cirrhosis1. While simple steatosis is quite benign with slow histological progression, 
NASH is associated with hepatic injury and inflammation; which can lead to the 
development of fibrosis and cirrhosis1.
The molecular mechanism triggering NASH is poorly understood. Histologically, NASH is 
manifested by inflammatory cell infiltration. Sustained inflammation in the liver is critical in 
the progression of NAFLD. Compelling data indicates that inflammatory cells play a key 
role in the initiation and perpetuation of the inflammatory response and the progression of 
liver disease in NASH2-4.
A histamine antagonist consists of two common types of drugs: histamine H1-receptor 
antagonists (H1RAs) and histamine H2-receptor antagonists (H2RAs). H1RAs are 
commonly used to treat allergic reactions5. H2RAs act on the H2 histamine receptors 
commonly found at the parietal cells on the gastric mucosa6. Blocking this receptor reduces 
gastric acid secretion6. Proton pump inhibitors (PPIs) are another class of drugs with potent 
inhibition of gastric acid secretion7. In addition to anti-allergic and anti-acid secretory 
effects, these medications have been found to have anti-oxidant properties and direct effects 
on inflammatory cells including monocytes that might prevent inflammation7-9. The anti-
inflammatory properties of these commonly used medications might influence the 
inflammatory cascades within and outside respiratory and gastrointestinal tracts.
There have been no reported human studies that explored the association between anti-
histamines or PPIs and NAFLD. The objective of this study was to investigate an association 
between anti-histamines or PPIs use and the prevalence of NAFLD in the US population 




The data were obtained from three continuous cycles of the NHANES conducted between 
2001 and 2006 using a complex, multistage, stratified, clustered, probability sample design 
to select a representative sample of the civilian, non-institutionalized US population. The 
three survey cycles of 13,248 participants included data interviews, physical examinations, 
Shen and Liangpunsakul Page 2





















and laboratory tests with blood and urine samples collection. Parameters were transformed 
according to the provided guidelines to make the data comparable between the cycles10. A 
detailed description of the survey and its sampling procedures are available elsewhere. The 
study was approved by the National Center for Health Statistics (NCHS) Ethics Review 
Board.
The inclusion criteria were age 20 – 74 years old and the availability of complete 
demographic, social, clinical, and laboratory data. We excluded 1,435 subjects without 
alanine aminotransferase (ALT) data and 1,415 subjects with conditions other than NAFLD 
that might cause serum aminotransferases elevation. These conditions included excessive 
alcohol consumption, viral hepatitis, iron overload, and use of medications associated with 
hepatotoxicity (androgens, antivirals medications, antifungals medications, nitrofuratoin, 
phenytoin, sulfonamides, trazadone, or tetracycline). A total of 10,398 participants were 
eligible for analysis (Figure 1).
 Data collection
Standardized questionnaires were used to obtain self-reported data on sex, age, race or 
ethnicity, education, income, smoking, alcohol consumption, physical activity, medical 
conditions, and drug use11. Body mass index was calculated based on the standardized 
measurements of height and weight. Systolic and diastolic blood pressure was considered 
the mean of six or fewer measurements obtained at the household interview (maximum of 
three) and the physical examination (maximum of three).
Race or ethnicity was categorized as non-Hispanic whites, non-Hispanic blacks, Mexican-
American, other Hispanics, and other, which included Aleut, Eskimo, American Indian, 
Asian or Pacific Islander. Education, according to completed years of schooling, was 
categorized as ≤ 8 years, 9 – 12 years, and ≥ 12 years. Economic status, according to the 
subject’s household income for the previous year, was categorized as ≤ $15,000, $15,001 – 
$25,000, and ≥ $25,000.
Smoking status was categorized as never, former, and current. Current smokers were defined 
as persons who reported having smoked > 100 cigarettes during their lifetime and who 
currently smoke some days or every day. Former smokers were those who reported having 
smoked > 100 cigarettes during their lifetime but did not smoke at the time of interview. 
Never smokers were those who smoked < 100 cigarettes during their lifetime12. Excessive 
alcohol consumption was defined as ≥1 drink/day for women and ≥2 drinks/day for men13. 
Participants were categorized as sedentary if they chose the option: “you sit during the day 
and do not walk about very much”.
Proton pump inhibitors (PPIs) or H1/H2-receptor antagonists (H1RAs/H2RAs) use was 
defined as the use of these medications during the month prior to the interview. The length 
of use was categorized as ≤ 60 days and > 60 days.
Insulin resistance was defined as a homeostasis of model assessment score (HOMA ) > 
3.014; elevated serum aminotransferases were defined as ALT > 40 U/L or aspartate 
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aminotransferase (AST) > 37 U/L in men, and ALT or AST > 31 U/ L in women; and 
transferrin saturation was considered as elevated when the values were ≥ 50%15.
 Definitions of NAFLD and controls
NAFLD was defined as the presence of elevated serum aminotransferases without any 
indication of other causes of chronic liver disease such as viral hepatitis infection (defined as 
a positive HCV RNA or HBsAg test), iron overload, or excessive alcohol consumption. This 
definition is in accordance with our previous study and previous publications on NAFLD 
using NHANES dataset16-18. Controls were defined as participants with normal liver 
enzymes and no evidence of chronic liver disease.
 Statistical analyses
Sample weights were used to account for nonresponse and unequal probabilities of selection. 
Stratum and sampling units accounted for the complex survey design using Taylor series 
linearization. Demographic and clinical differences between study participants with and 
without prevalent NAFLD were compared using the student t-test or chi-square test, as 
appropriate. Unconditional multivariate logistic regression was used to assess the association 
between PPIs or H1RAs/H2RAs and NAFLD. Potential confounders, which included age, 
sex, ethnicity, socioeconomic status, BMI, physical activity, smoking status, diabetes or 
insulin resistance, hypertension or systolic/diastolic blood pressure, hypercholesterolemia or 
serum total cholesterol, triglycerides, high-density lipoprotein (HDL), and low-density 
lipoprotein (LDL), were assessed in stepwise regression models. The final models included 
for age, sex, ethnicity, socioeconomic status, waist circumference, physical activity, smoking 
status, insulin resistance (IR), systolic/diastolic blood pressure, and hypercholesterolemia as 
covariates. We also conducted analyses stratified on other risk factors, including sex, age, 
insulin resistance, hypertension, hypercholesterolemia, body mass index (BMI), and 
physical activity. All analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, 
USA). A p-value ≤ 0.05 (2-sided) was considered statistically significant.
 RESULTS
 Demographic and clinical characteristics of the study participants
Of the 10,398 participants included for the main analyses, 2,058 were identified as having 
NAFLD and 8,340 as controls. Selected characteristics of the study participants, according 
to NAFLD status, are summarized in Table 1. On average, participants with NAFLD were 
nearly 1.5 years younger and had higher systolic and diastolic blood pressures; higher serum 
triglycerides and total and LDL-cholesterol and lower HDL-cholesterol levels; and higher 
circulating glycated hemoglobin, liver enzymes, and uric acid levels. Those with NAFLD 
were more likely to be men, obese, and Mexican-American. They had less education with 
higher prevalence of insulin resistance. Participants with NAFLD were less likely to take 
H1RAs/H2RAs and more likely to take PPIs in the prior month.
 Associations of H1RAs/H2RAs and PPIs and the prevalence of NAFLD
The results are summarized in Tables 2 and 3. After adjustment for potential confounders, 
the use of H2RAs was significantly associated with lower prevalence of NAFLD by 57% 
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regardless of the length of use, when compared to those who did not take H2RAs. The 
decreasing in the prevalence of NAFLD among H2RA users was only observed in men (OR 
0.18, 95%CI 0.04-0.79) and those with insulin resistance (OR 0.22, 95%CI 0.05-0.95). 
There was no difference in the prevalent NAFLD among H1RA and PPI users (Tables 2, 4 
and 5).
 DISCUSSION
Our cross-sectional study results to investigate an association of H1RAs/H2RAs or PPIs use 
with NAFLD suggest that only the use of H2RAs was associated with a lower prevalence of 
NAFLD in the general US population, primarily among men and those with insulin 
resistance.
The pathogenesis of NAFLD and the progression to NASH are complex, involving a 
combination of lipid oxidation, oxidative stress, inflammatory cells as well as 
proinflammatory cytokines1, 16. Alterations in lipid metabolism drive the polarization of the 
Kupffer cells into the proinflammatory phenotype; which trigger the recruitment of 
inflammatory cells and the progression of underlying NAFLD 2. Several signaling cascades 
are also affected. Among them are the NFκB and the c-Jun-N terminal kinases (JNK). Their 
activation contribute to worsening steatosis and hepatic inflammation2.
Histamine antagonists and PPIs are two medication classes which are most commonly used 
in the United States19. There are several proposed molecular mechanisms underlying the 
possible effectiveness of histamine antagonists and PPIs against NAFLD. Histamine can 
influence numerous functions of the cells involved in the regulation of immune response 
including macrophages20. In fact, macrophages express histamine receptors and also secrete 
histamine, which can selectively recruit the major effector cells into tissue leading to chronic 
inflammation20. Because of these reasons, it is speculated that modulation of histamine’s 
function through the use of antagonists might interfere with its inflammatory effects. In fact, 
several studies have shown that both H1RAs and H2RAs suppress inflammatory responses 
via inhibition of NFκB, p38 MAP, and JNK8, 21, 22. PPIs are potent blockers of gastric acid 
secretion and have been found to have anti-oxidant properties through their effects on 
inflammatory cells thus mitigating inflammation7, 23.
We found that only H2RAs were significantly associated with lower prevalence of NAFLD. 
The explanation of our observations is unclear. . Though H1RAs and H2RA2 have been 
shown to inhibit inflammation9, their role in the pathogenesis of NAFLD is still elusive. In 
fact, a previous study found that H1RAs exacerbate high fat diet-induced hepatic steatosis in 
mice24. While NAFLD with hepatic triglyceride accumulation was observed in H2RA null 
mice25, the study by Wake et al., on the other hand, found that H2RAs inhibit the expression 
and the production of inflammatory cytokines in human peripheral blood mononuclear 
cells26. Additionally, though some of the anti-inflammatory actions that have been observed 
by PPIs, it is not clear that oral PPIs dosing can achieve the high drug concentrations in 
plasma and tissue to reproduce the effect observed in vitro studies7.
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The gender difference on the effect of H2RAs and the prevalence of NAFLD deserves 
further discussion. Flores et al conducted a study to determine if differences exist in the 
pharmacokinetic (PK) parameters of oral ranitidine caused by gender. Twenty subjects (10 
men and 10 women) were enrolled when subjects received a tablet dose of 300 mg ranitidine 
(H2RA) and blood samples were drawn at several times after its ingestion for the PK 
analysis. It is interesting that the clearance of the medication was higher in women27. In 
another ranitidine PK study of 16 healthy volunteers (8 men and 8 women), the oral 
clearance is ~10.5% higher in women than that in men28. It is plausible that our findings 
reflect the gender differences in the PK of H2RAs.
It is unclear on why the effect of H2RAs is primarily observed in patients with insulin 
resistance. Gentile et al. evaluated the role of ranitidine on glucose, insulin levels in 9 
healthy volunteers. Interestingly they found that ranitidine infusion influences hepatic 
clearance of glucose and insulin29. The effect of H2RAs on insulin/glucose hemostasis and 
its effect on NAFLD might need to be investigated further.
This study has several limitations. First, the cross sectional study design of NHANES 
prohibits the assessment for the causality between the use of H2RAs and NAFLD 
association. It is also important to note that the NHANES dataset only reports prescription 
medication use. Several H1RAs, H2RAs and PPIs are available without a prescription. It is 
possible that there were participants taking these medications from the over the counter 
sources which were not captured in the dataset. Additionally, the information on the exact 
doses of these medications and the duration of administration are also lacking. The study 
design also disallows us to determine the compliance with the medications in these subjects. 
Second, the data on inflammatory markers such as TNF alpha are not available. Hence, we 
cannot directly test the differences in their levels in these subjects, stratified by anti-
histamine or PPI use. Lastly, the diagnosis of NAFLD was based on serum 
aminotransferases, but not confirmed by ultrasonography or liver biopsy; therefore, some 
study participants may have been misclassified as having NAFLD or not. We and others 
have used the definition of abnormal ALT in subjects without excessive alcohol use and 
other chronic liver disease etiologies, as the indirect marker for the presence of 
NAFLD18, 30, 31. In fact, when compared to those with normal ALT, these subjects were 
more obese and had several features of metabolic syndrome mimicking those with 
NAFLD18. Despite these weaknesses, our study is strengthened by the sample size and the 
study cohort representing the US population.
In conclusion, we found that the use of H2RAs may be associated with a lower prevalence of 
NAFLD, primarily among men with insulin resistance. Further studies are needed to confirm 
our observation.
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Figure 1. Schematic diagram on the selection of the study participants
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Table 1
Selected characteristics of the study participants, according to NAFLD prevalence; 








Age (yrs.) 44.8 ± 0.2 43.2 ± 0.3 < 0.01
Men (%) 39.8 ± 0.5 66.2 ± 1.0 < 0.01
Race or ethnicity (%)
 Mexican-American 21.4 ± 0.4 30.4 ± 1.0
< 0.01
 Other Hispanic 3.5 ± 0.2 5.3 ± 0.5
 Non-Hispanic White 48.6 ± 0.5 45.5 ± 1.1
 Non-Hispanic Black 22.4 ± 0.5 15.0 ± 0.8
 Other 4.1 ± 0.2 3.7 ± 0.4
Annual household income (%)
 ≤ $15,000 13.9 ± 0.4 11.9 ± 0.7
0.03 $15,001 – $25,000 15.1 ± 0.4 14.4 ± 0.8
 > $25,000 71.0 ± 0.5 73.7 ± 1.0
Education (%)
 ≤ 8 years 11.4 ± 0.3 14.8 ± 0.8
< 0.01 9 – 12 years 15.2 ± 0.4 14.9 ± 0.8
 > 12 years 73.3 ± 0.5 70.3 ± 1.0
Body mass index (kg/m2) 28.5 ± 0.1 30.3 ± 0.1 < 0.01
Waist circumference (cm) 96.7 ± 0.2 102.3 ± 0.3 < 0.01
Physical activity (Sedentary) (%) 23.3 ± 0.5 21.6 ± 0.9 0.10
Smoking status (%)
 Never smokers 54.8 ± 0.5 53.6 ± 1.1
0.07 Former smokers 23.0 ± 0.5 25.4 ± 1.0
 Current smokers 22.1 ± 0.5 21.0 ± 0.9
Diabetes†(%) 9.9 ± 0.3 8.6 ± 0.6 0.09
Hypertension†(%) 28.2 ± 0.5 28.6 ± 1.0 0.78
Hypercholesterolaemia†(%) 39.3 ± 0.7 44.9 ± 1.4 < 0.01
Insulin resistance ¥ (%) 32.0 ± 0.7 56.2 ± 1.6 < 0.01
Glycated hemoglobin (%) 5.5 ± 0.01 5.7 ± 0.02 < 0.01
Systolic BP (mm Hg) 122.0 ± 0.2 123.3 ± 0.4 < 0.01
Diastolic BP (mm Hg) 70.0 ± 0.1 72.9 ± 0.3 < 0.01
Serum triglycerides (mmol/L) 1.6 ± 0.02 2.1 ± 0.06 < 0.01
Serum total cholesterol (mmol/L) 5.2 ± 0.01 5.4 ± 0.03 < 0.01
Serum LDL-cholesterol (mmol/L) 3.0 ± 0.01 3.2 ± 0.04 < 0.01





























Serum HDL cholesterol (mmol/L) 1.4 ± 0.005 1.2 ± 0.008 < 0.01
Serum alanine aminotransferase
(U/L)
19.4 ± 0.1 47.0 ± 1.0 < 0.01
Serum aspartate aminotransferase
(U/L)
21.4 ± 0.1 35.9 ± 0.5 < 0.01
Serum γ-glutamyltransferase (U/L) 21.8 ± 0.2 48.4 ± 1.5 < 0.01
Serum uric acid (μmol/L) 303.1 ± 0.9 345.7 ± 1.9 < 0.01
PPIs use (%) 6.1 ± 0.3 6.4 ± 0.5 0.59
H2RAs use (%) 1.8 ± 0.1 1.7 ± 0.3 0.91
H1RAs use (%) 3.4 ± 0.2 2.7 ± 0.4 0.14
*Values are percentages ± standard errors (SE) for categorical variables and means ± SE for continuous variables
£
From Student t-test for continuous variables and chi square test for categorical variables
†Self-reported doctor diagnosis and medication use
¥
Insulin resistance was defined as a homeostasis of model assessment score, or HOMA, > 3.0
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Table 2
Association of proton-pump inhibitors (PPIs) or H1/H2-receptor antagonists (H1RAs/
H2RAs) use with prevalent NAFLD; NHANES, 2001 – 2006
Crude OR (95% CI) Adjusted¥ OR (95%
CI)
PPIs use
 No 1.00 1.00
 Yes 1.06 (0.87 – 1.29) 0.97 (0.67 – 1.39)
Length of
use
 Never 1.00 1.00
 ≤ 60 days 1.31 (0.77 – 2.23) 0.86 (0.24 – 3.08)
 > 60 days 1.03 (0.83 – 1.27) 0.98 (0.67 – 1.43)
Ptrend* = 0.70
H2RAs use
 No 1.00 1.00
 Yes 0.98 (0.68 – 1.41) 0.43 (0.18 – 0.99)
Length of
use
 Never 1.00 1.00
 ≤ 60 days 1.74 (0.79 – 3.80) 0.47 (0.05 – 3.97)
 > 60 days 0.85 (0.56 – 1.30) 0.42 (0.16 – 1.09)
Ptrend* = 0.67
H1RAs use
 No 1.00 1.00
 Yes 0.80 (0.60 – 1.07) 0.78 (0.46 – 1.31)
Length of
use
 Never 1.00 1.00
 ≤ 60 days 1.07 (0.57 – 2.03) 0.44 (0.05 – 3.61)
 > 60 days 0.75 (0.54 – 1.04) 0.81 (0.47 – 1.40)
Ptrend* = 0.10
Abbreviations: NAFLD, non-alcoholic fatty liver disease; NHANES, National Health and Nutrition Examination Survey; OR, odds ratio; CI, 
confidence interval; IR, insulin resistance
*Cochran-Armitage trend test
¥Unconditional logistic regression model, adjusted for age, sex, ethnicity, socioeconomic status, waist circumference, physical activity, smoking 
status, insulin resistance (IR), systolic/diastolic blood pressure, and hypercholesterolemia
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Table 3
Association of H2-receptor antagonists (H2RAs) use with prevalent NAFLD according to 
selected risk factors; NHANES, 2001 – 2006
Crude OR (95% CI) Adjusted¥ OR (95% CI)
Sex
  Male 0.88 (0.55 – 1.42) 0.18 (0.04 – 0.79)
  Female 1.04 (0.57 – 1.92) 0.78 (0.26 – 2.35)
Age
  ≤ 60 yrs. 1.03 (0.62 – 1.69) 0.39 (0.11 – 1.38)
  > 60 yrs. 1.25 (0.72 – 2.17) 0.46 (0.13 – 1.57)
BMI
 < 25 2.20 (0.94 – 5.12) 2.15 (0.53 – 8.75)
 25-30 0.93 (0.51 – 1.69) 0.31 (0.07 – 1.37)
 ≥ 30 0.66 (0.37 – 1.15) 0.13 (0.02 – 1.05)
IR
 No 0.80 (0.34 – 1.88) 0.72 (0.25 – 2.11)
 Yes 0.33 (0.13 – 0.86) 0.22 (0.05 – 0.95)
OR, odds ratio; CI, confidence interval; IR, insulin resistance
¥Unconditional logistic regression model, adjusted for PPIs and H1RAs use, age, sex, ethnicity, socioeconomic status, waist circumference, 
physical activity, smoking status, insulin resistance (IR), systolic/diastolic blood pressure, and hypercholesterolemia
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Table 4
Association of H1-receptor antagonists (H1RAs) use with prevalent NAFLD according to 
selected risk factors; NHANES, 2001 – 2006
Crude OR (95% CI) Adjusted¥ OR (95%
CI)
Sex
  Male 1.12 (0.76 – 1.65) 1.20 (0.62 – 2.32)
  Female 0.65 (0.40 – 1.06) 0.34 (0.11 – 1.13)
Age
  ≤ 60 yrs. 0.74 (0.53 – 1.02) 0.74 (0.39 – 1.40)
  > 60 yrs. 1.16 (0.63 – 2.13) 1.05 (0.39 – 2.82)
BMI
 < 25 0.48 (0.19 – 1.19) 0.79 (0.17 – 3.62)
 25-30 0.94 (0.60 – 1.48) 1.01 (0.46 – 2.23)
 ≥ 30 0.78 (0.50 – 1.21) 0.54 (0.24 – 1.24)
IR
 No 0.57 (0.28 – 1.13) 0.83 (0.38 – 1.78)
 Yes 0.96 (0.55 – 1.69) 0.77 (0.37 – 1.62)
OR, odds ratio; CI, confidence interval; IR, insulin resistance
¥Unconditional logistic regression model, adjusted for PPIs and H2RAs use, age, sex, ethnicity, socioeconomic status, waist circumference, 
physical activity, smoking status, insulin resistance (IR), systolic/diastolic blood pressure, and hypercholesterolemia
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Table 5
Association of proton-pump inhibitors (PPIs) use with prevalent NAFLD according to 
selected risk factors; NHANES, 2001 – 2006
Crude OR (95% CI) Adjusted¥ OR (95% CI)
Sex
  Male 0.85 (0.65 – 1.12) 0.98 (0.59 – 1.62)
  Female 1.44 (1.08 – 1.93) 0.98 (0.56 – 1.70)
Age
  ≤ 60 yrs. 1.34 (1.06 – 1.70) 1.09 (0.67 – 1.77)
  > 60 yrs. 0.86 (0.59 – 1.26) 0.75 (0.42 – 1.35)
BMI
 < 25 1.30 (0.77 – 2.19) 1.17 (0.48 – 2.90)
 25-30 0.80 (0.56 – 1.14) 0.92 (0.49 – 1.75)
 ≥ 30 1.07 (0.81 – 1.40) 1.05 (0.62 – 1.78)
IR
 No 0.72 (0.44 – 1.17) 0.76 (0.41 – 1.40)
 Yes 1.07 (0.75 – 1.53) 1.10 (0.69 – 1.76)
OR, odds ratio; CI, confidence interval; IR, insulin resistance
¥Unconditional logistic regression model, adjusted for H1RAs and H2RAs use, age, sex, ethnicity, socioeconomic status, waist circumference, 
physical activity, smoking status, insulin resistance (IR), systolic/diastolic blood pressure, and hypercholesterolemia
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